{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037578","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.384387+00:00","generated_at":"2026-06-12T09:11:46.262699+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kymera Q2 net loss $38.8M; cash $472M; Sanofi to start KT-474 Phase 2 in Q4 2023","bullets":["Collaboration revenue $16.5M (up from $11.5M YoY); R&D expense $45.8M; net loss narrowed to $38.8M.","Cash & equivalents $472M as of June 30, 2023; cash runway into second half of 2025.","Partner Sanofi plans Phase 2 trials for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in Q4 2023.","Phase 1 data for KT-253 (MDM2), KT-333 (STAT3), KT-413 (IRAKIMiD) expected later in 2023.","Appointed Jeremy Chadwick as COO and Justine Koenigsberg as VP, Head of IR."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037578","json":"https://secwatch.observer/filing/0000950170-23-037578.json","markdown":"https://secwatch.observer/filing/0000950170-23-037578.md","text":"https://secwatch.observer/filing/0000950170-23-037578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023037578/0000950170-23-037578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023037578/kymr-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:11:46.262699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f69242cca8368da388bb2773ecd8276d31c197d","claim":"Kymera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $16.5 million.","evidence_excerpt":". A replay of the webcast will be archived and available following the event. Second Quarter 2023 Financial Results Collaboration Revenues: Collaboration revenues were $16.5 million for the second quarter of 2023 compared to $11.5 million for the second quarter of 2022. Collaboration revenues include revenue from the Company’s Sanofi and Vertex","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023037578/0000950170-23-037578-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$16.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}